

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

**ANNOUNCEMENT  
INSIDE INFORMATION**

**ASC09 FIXED-DOSE COMBINATION AND RITONAVIR OBTAINED APPROVAL FROM  
WUHAN TONGJI HOSPITAL ETHICS COMMITTEE TO CONDUCT CLINICAL TRIAL  
ON THE TREATMENT OF NEW CORONAVIRUS INFECTIONS**

This announcement is made by Ascletis Pharma Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company began scientific cooperation with Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology. The investigator-initiated clinical research, led by Dr. Qin Ning team, on “A Randomized, Open-label, Controlled Phase III Small-sample Clinical Trial Evaluating the Safety and Efficiency of ASC09/Ritonavir Fixed-dose Combination, Ritonavir for Confirmed Cases of Pneumonia Caused by New Coronavirus Infection”, has obtained approval from the Ethics Committee of Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology. Dr. Qin Ning is the deputy chairman of the Division of Infectious Diseases of the Chinese Medical Association and director of the Infectious Diseases Institute of Wuhan Tongji Hospital. The Company will inform the public of the progress of such clinical trial in a timely manner.

Capitalized terms used but not otherwise defined herein shall have the same meaning as that ascribed to them in the announcement of the Company dated February 3, 2020 in relation to the latest progress regarding the use of ASC09 fixed-dose combination and Ritonavir for the treatment of the new coronavirus (2019-nCoV) infections.

**Cautionary Statement required by Rule 18A.05 of the Listing Rules:** We cannot guarantee that we will be able to obtain approval for, or ultimately market, Ritonavir and ASC09 fixed-dose combination, successfully.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Ascleitis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hangzhou, the People's Republic of China,  
February 5, 2020

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; Dr. Ru Rong JI, Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*